Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Photrex (rostaporfin) photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
2005-001856-19Phase 3Terminated
- Sponsor
- Miravant Medical Technologies
- Start
- Sep 2005
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Rostaporfin in exudative macular degeneration (2 arms), sponsored by Miravant Medical Technologies. Primary endpoints: Visual acuity preservation at Week 51 and Visual acuity preservation at Week 103. Started Sep 2005; status: terminated.
02
Drugs
Rostaporfin
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2005-001856-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001856-19.